title: Requirement of catalytically active Tyk2 and accessory signals for the induction of TRAIL mRNA by IFN-beta.
abstract: Tumor necrosis factor (TNF)-related apoptosis-inducing ligand/Apo2 ligand (TRAIL/Apo2L) mRNA was induced preferentially by interferon (IFN)-beta but not IFN-alpha in human fibrosarcoma and primary fibroblast cells. To characterize the signaling components mediating the IFN subtype-specific induction of this gene, we used mutant cell lines lacking individual components involved in signaling by type I IFNs. TRAIL was not induced by IFN-beta in mutant cell lines U2A, U3A, U4A, U5A, and U6A, which lack, respectively, IFN regulatory factor-9 (IRF-9), Stat1, Jak1, IFNAR-2.2, and Stat2, indicating transcription factor IFN-stimulated gene factor 3 (ISGF3) was essential for the induction of this gene. TRAIL was not induced by IFN-beta in U1A (Tyk2 null) or U1A.R930 cells (that express a kinase-deficient point mutant of Tyk2) but was induced in U1A.wt-5 cells (U1A cells expressing wild-type Tyk2), indicating that Tyk2 protein and kinase activity were both required for induction of the gene. Biochemical and genetic analyses revealed the requirement of transcription factor NF-kappa B and phosphoinositide 3-kinase (PI3K) but not extracellular signal-regulated kinase (ERK) for the induction of TRAIL by IFN-beta. Furthermore, the antiproliferative but not antiviral effects of IFN-beta required catalytically active Tyk2, suggesting that expression of genes, such as TRAIL, may play an important role in mediating the biologic effects of IFNs.
authors: Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
authors: M R Sandhya
authors: MR
authors: Rani
authors: Sudha
authors: S
authors: Pandalai
authors: Jennifer
authors: J
authors: Shrock
authors: Alex
authors: A
authors: Almasan
authors: Richard M
authors: RM
authors: Ransohoff
mesh_terms: D000107:Acetylation; D017209:Apoptosis; D045744:Cell Line, Tumor; D006657:Histones / Q000378:metabolism; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology; D000068576:Interferon beta-1b; D050832:Interferon-Stimulated Gene Factor 3 / Q000378:metabolism; D016899:Interferon-beta / Q000494:pharmacology*; D016328:NF-kappa B / Q000378:metabolism; D020411:Oligonucleotide Array Sequence Analysis; D011401:Promoter Regions, Genetic; D012333:RNA, Messenger / Q000378:metabolism; D011994:Recombinant Proteins; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000235:genetics* / Q000378:metabolism*; D053634:TYK2 Kinase / Q000378:metabolism*
chemical_list: D006657:Histones; D007370:Interferon Type I; D050832:Interferon-Stimulated Gene Factor 3; D016328:NF-kappa B; D012333:RNA, Messenger; D011994:Recombinant Proteins; D053221:TNF-Related Apoptosis-Inducing Ligand; D000068576:Interferon beta-1b; D016899:Interferon-beta; D053634:TYK2 Kinase; C070139:TYK2 protein, human